Vyant Bio soars on drug discovery deal for Parkinson's disease

Vyant Bio

30/03/2022 11:37

** Shares of biotech co  VYNT.O  jump ~55% to $2.09 before
the bell; on track to hit their highest level in over four
months, if gains hold 
    ** Stock among top pct gainers on the Nasdaq  .IXIC 
premarket 
    ** VYNT to collaborate with OrganoTherapeutics to expedite
the discovery of drugs for treatment of Parkinson's Disease (PD)
 urn:newsml:reuters.com:*:nGNX3FPqWS 
    ** Parkinson's is a brain disorder that causes shaking and
difficulty with walking, balance and coordination, and worsens
over time
    ** Companies will combine OrganoTherapeutic's 3D-organoid
disease models and VYNT's machine-learning technology
AnalytiX to identify potential PD drugs
    ** OrganoTherapeutics is a spin-off from the Luxembourg
Centre for Systems Biomedicine (LCSB) of the University of
Luxembourg
    ** Up to Tuesday's close, VYNT down ~7% YTD 
    

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))